InspireMD, Inc., a leader in embolic protection systems, today announced that Professor Joachim Schofer, MD, at the Hamburg University Cardiovascular Center, will present the results of the CARENET (CARotid Embolic protection using microNET) trial at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in Washington, D.C. on Tuesday September 16, 2014.

Boston Scientific Corporation has initiated full commercial launch of the new POLARIS Imaging System.  This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products.  The POLARIS System offers enhanced ease-of-use and more powerful processing capabilities.  Its modular design would also support the planned release of new Boston Scientific imaging products including a fractional flow reserve (FFR) wire, a new family of IVUS catheters, enhanced software features and better system control tools.

Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation  has received CE Mark and begun the European market launch of the Agent Paclitaxel-Coated PTCA Balloon Catheter.  The Agent Drug-Coated Balloon (DCB) provides physicians with an additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel coronary disease.

Due to rapidly increasing demand for its cardiac cath lab PCI, Diagnostic and Carotid Stenting accreditation and quality review services, ACE is proud to lead the way in offering four new accreditation and external review services for catheter based cardiovascular procedures to include: Congenital Heart Disease, Electrophysiology including Implants & Devices, Transcatheter Valve Therapies and Peripheral Vascular Procedures.

A Brazilian soccer fan died after experiencing an MI at the close of a dramatic World Cup match between Brazil and Chile that allowed Brazil to advance to the quarter finals.

Moving toward U.S. market introduction of its novel medical device to treat peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that it recently submitted the final module of its pre-market approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration (FDA). The application includes data that demonstrates superior clinical outcomes compared with conventional angioplasty, with the lowest rates of repeat procedures (target lesion revascularization) and the highest rate of uninterrupted blood flow (primary patency) at 12 months ever reported for the interventional treatment of peripheral artery disease.

The Accreditation for Cardiovascular Excellence (ACE) is proud to announce the participation of every ACE Board Member at the 2014 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las Vegas, NV, May 28-31, 2014. First, Charles E. Chambers, MD, FSCAI, President-Elect of SCAI and ACE Board Member, will kick-off SCAI's inaugural Cath Lab Leadership Boot Camp, a unique two-day educational event designed to address the needs of cath lab managers and directors and those who aspire to those roles.

Covidien today announced nine-month data from the VISIBILITY Iliac study, which confirms the safety and effectiveness of the treatment of lesions of the common and external iliac arteries with the Visi-Pro(tm) balloon-expandable stent system. Results were presented by co-National Principal Investigator John Rundback, MD, Holy Name Medical Center, Teaneck, N.J., during an oral presentation this week at EuroPCR Scientific Congress in Paris.